Zhejiang Angda Jiuli Biopharmaceutical Co., Ltd.

Zhejiang Angda Jiuli Biopharmaceutical Co., Ltd. is a high-tech biopharmaceutical enterprise based in China and looking to the world, integrating R&D, production and sales operations. The company's core product is recombinant exenatide human serum albumin fusion protein, referred to as E2HSA (Chinese: Zhou Kening), which has obtained the national invention patent certificate. It is an anti-type II diabetes ultra-long-acting biological innovative drug produced by recombination and optimization on the basis of yeast cultivation. 

E2HSA, with its long-term advantages of high purity, good hypoglycemic effect, small toxic and side effects, and once-a-week administration, has changed the traditional diabetes treatment method and provided a new treatment plan for type II diabetes patients. The birth of E2HSA products marks a major change in the treatment of diabetes in China. It has broad prospects in the application of anti-diabetic drugs, will bring new hope to tens of thousands of diabetic patients, and will promote China's biopharmaceutical technology to the forefront of the world!